Status:
COMPLETED
Famotidine in Subjects With Non-erosive Gastroesophageal Reflux Disease
Lead Sponsor:
Astellas Pharma Inc
Conditions:
Gastroesophageal Reflux
Eligibility:
All Genders
20+ years
Phase:
PHASE2
PHASE3
Brief Summary
Gastroesophageal reflux disease (GERD) considered to be associated with mucosal damages in the esophagus and heartburn, which may sometimes interfere with daily activities due likely to reflux of acid...
Eligibility Criteria
Inclusion
- Patients have heartburn with non-erosive gastroesophageal reflux disease.
Exclusion
- Patients have diseases which interfere with evaluation of the efficacy and safety in this study.
- Patients are receiving and/or have received prior to the enrollment the treatment which interfere with evaluation of the efficacy and safety in this study.
- Patients have severe cardiovascular, hepatic, renal and hematological disorders.
- Patients are allergic to or have a history of drug allergy to H2RA.
- Patients have or have a history of malignant tumors.
- Patients are pregnant or a lactating mother.
- Patients have participated in other clinical studies less than 12 weeks prior to submitting the informed consent.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
480 Patients enrolled
Trial Details
Trial ID
NCT00141960
Start Date
September 1 2005
Last Update
November 21 2011
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Hokkaido Region, Japan
2
Kanto Region, Japan
3
Kinki Region, Japan
4
Kyushu Region, Japan